Targeted radiation for cancer of unknown primary
Part of Cancer clinical trials.
This trial tests a radioactive medicine (Lu-177 FAP-2286) that seeks out and delivers radiation directly to cancer cells. It is for people whose cancer started in an unknown place and has not responded to their first chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with cancer of unknown primary (CUP).
- Your cancer has not responded to one line of platinum-based chemotherapy (with or without immunotherapy).
- Your tumor shows high uptake on a special PET scan (68Ga-FAPI-46).
- You have at least one tumor that can be measured on scans.
- You are able to have a biopsy if needed.
- You have not had more than one line of systemic treatment for this cancer.
- Your kidney, liver, and blood counts are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with cancer of unknown primary (CUP), meaning cancer that started in an unknown place in the body. It aims to use advanced genomic testing (looking at your tumor's DNA) on your stored tumor sample and blood to find clues about where the cancer began and possible treatment options.
This study tests a new type of PET-CT scan using a tracer called FAPI to find the original source of cancer when standard tests have not been able to. It may help identify the primary tumor in people with cancer that has spread from an unknown location.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial tests a new drug (F520) combined with two chemotherapy drugs for people whose cancer started in an unknown place in the body. It aims to see if the combination shrinks tumors and is safe.
This trial tests a special radioactive medicine (177Lu-CTR-FAPI) for people with advanced digestive cancers that have high FAP expression. The medicine targets a protein on cancer cells to deliver radiation directly to tumors, potentially slowing their growth.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Hear when a new Cancer of Unknown Primary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.